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(Figure 2). Given the changes of the left breast reminiscent
of IBC, punch biopsy of the breast skin was performed.
Results showed dermal angiolymphatic ectasia and benignntroduction
on-Hodgkin lymphomas (NHL) are a heterogeneous group of
ymphoproliferative disorders originating in lymphocytes or
atural killer cells with most cases being B-cell lymphomas.
he typical presentation is of a rapidly enlarging tumor mass
t single or multiple nodal sites although up to 40% of patients
ay have disease initially conﬁned to extranodal structures.1
Inﬂammatory breast carcinoma (IBC) is a rare and particu-
arly aggressive form of breast cancer, characterized by rapid
nset of erythema and edema (peau d’orange) occupying at
east one-third of the breast. The diagnosis is made on clin-
cal grounds associated with pathological documentation of
nvasive carcinoma in the breast parenchyma.2,3
We  describe a female patient with an enlarged, ery-
hemic and edematous left breast, regional adenopathy and
oorly differentiated carcinoma on hematoxylin and eosin
H&E) staining, who  after proper imaging and immunohis-
ochemistry proved to have a high-grade axillary B-cell NHL
resenting under the guise of IBC.∗ Corresponding author at: Hospital Dona Helena, Setor de Oncologia C
E-mail  address: ribaschristian@hotmail.com (C. Ribas).
ttp://dx.doi.org/10.1016/j.bjhh.2015.08.007
516-8484/© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia
eserved.Case  report
A 66-year-old woman presented with a 3-month history of
left breast enlargement, erythema and peau d’orange skin
edema (Figure 1). There was no palpable nodule or nipple
discharge. The erythema extended into the left axilla, where a
voluminous, ill-deﬁned mass was identiﬁed. No other masses
or lesions of the right breast or elsewhere were noted on the
exam. Bilateral mammography and breast ultrasound showed
abnormalities of the left breast: skin thickening, diffusely
hyperechogenic breast parenchyma, dilated intramammary
lymphatics and a hypoechogenic mass (extensive adenopa-
thy) in the left axilla; no nodules or microcalciﬁcations
were apparent. Such ﬁndings were also apparent on a chest
computed tomography (CT) scan (Figure 1). Incisional biopsy
of the axillary mass was carried out. H&E sections revealed
subcutaneous inﬁltration by poorly differentiated carcinomalínica, Rua Blumenau, 123, 89204-250, Joinville, SC, Brazil.
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Figure 1 – Clinical features. (A) Erythema and peau d’orange skin edema. (B) Asymmetric skin thickening and stromal edema
h noof the left breast on a computed tomography scan. (C) Lymp
perivascular lymphocytes; a deep core biopsy of the breast
parenchyma showed similar histologic features with no
neoplastic cells. The immunohistochemistry panel (CD20+
diffuse; CD3− Ki-67+ in 80% of cells; negativity for the
epithelial antigens AE1/AE3, estrogen receptor, progesterone
receptor, Her2-neu) supported the diagnosis of high-grade
B-Cell NHL (Figure 2). Signiﬁcant constitutional symptoms
were absent. Staging procedures (chest and abdominopelvic
CT scans, positron emission-computed tomography (PET-
CT), cerebrospinal ﬂuid analysis, bone marrow smear and
biopsy) revealed stage IVA, high-risk international prog-
nostic index (IPI) 4 disease, with mediastinal adenopathies,
matted lymph nodes forming a 6.8 cm mass involving the
adipose tissue of the left axilla, and multiple secondary lung
and splenic nodules. The patient was treated with eight
cycles of systemic chemotherapy (R-CHOP-21: rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone),
cycling every 21 days, and central nervous system prophy-
laxis with intrathecal methotrexate. The treatment was
well tolerated, resulting in complete resolution of breast
abnormalities and systemic disease control on interval CT
scans. PET-CT at the end of chemotherapy showed the dis-
ease had disappeared from all sites apart from a residual,
Figure 2 – Histologic features. (A) Poorly differentiated carcinoma
diffuse reactivity for CD20 (magniﬁcation 400×). (C) Negativity fode mass in the left axilla on a computed tomography scan.
involuted and metabolically faint left axillary adenopathy,
with only extensive coagulative necrosis on resection. Three
years after the diagnosis, the patient remains in complete
remission.
Discussion
NHL are a heterogeneous group of lymphoproliferative disor-
ders with distinct clinical and pathologic features. In Brazil,
they are among the twelve most frequent cancers in both men
and women, with an estimated incidence of 9918 new cases
in 2015.4,5
Diffuse large B-cell lymphoma is the most common NHL,
accounting for around 30% of adult cases in western countries.
Although a percentage of NHL patients may initially have
disease conﬁned to extranodal structures, the typical presen-
tation is of a rapidly enlarging tumor mass at a single or
multiple nodal sites.1IBC is a relatively rare clinicopathologic entity that
accounts for 2% of invasive breast cancers.2 IBC represents
the most aggressive type of breast cancer, being character-
ized by rapid onset of erythema and edema (peau d’orange)
 (hematoxylin and eosin: magniﬁcation 400×). (B) Strong
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ccupying at least one-third of the breast. The skin changes
re caused by dermal lymphatic involvement by malignant
ells, whose presence on punch biopsy is pathognomonic of
BC. Despite the occasional absence of a palpable breast mass,
ost cases of IBC have locoregional disease (metastases to
xillary/supraclavicular nodes) and about 30% have stage IV
etastatic disease at diagnosis. The diagnosis is based on clin-
cal characteristics with essential pathological conﬁrmation of
nvasive carcinoma.3
The clinical characteristics of IBC are rather unusual for
HLs, being occasionally reported in uncommon cases of
rimary or secondary breast involvement by lymphomas.6,7
odal axillary NHL, however, may also take on the appearance
f IBC,8 even in the absence of direct breast involve-
ent as highlighted herein. Presumably, this would occur
ecause of lymph-vascular engorgement and the resultant
kin changes.
Although, by routine H&E staining our patient had the ini-
ial diagnosis of invasive carcinoma, which makes lymphoma
ess plausible, NHL may sometimes appear as poorly differ-
ntiated carcinoma by conventional histology. Negativity for
ytokeratins (e.g. AE1/AE3) and strong positivity for the leuko-
yte common antigen and CD20 allow the diagnosis of B-cell
HL to be made.9
As the incidence of lymphomas, particularly B-cell lym-
homas, is increasing worldwide,1 it is important to be aware
f their most uncommon presentations. Axillary nodal NHL
ith reactive breast/skin changes should then be included
mong the differential diagnoses of IBC, together with
ther entities such as acute mastitis, breast lymphoma and
xtramammary carcinomas metastatic to the breast; such dis-
inction is of paramount importance since the prognoses and
anagement are substantially diverse.
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